Rapid Diagnostic Expansion HiberGene Diagnostics offers a growing portfolio of rapid, highly accurate molecular tests for infectious diseases, including COVID-19, Flu, and bacterial meningitis, presenting opportunities to meet urgent diagnostic needs in hospitals, clinics, and laboratories.

Regulatory Milestones With recent CE Marking approval for combined COVID-19 and Flu testing, the company is positioned to expand into European markets and strengthen its presence in infectious disease diagnostics, appealing to healthcare providers seeking validated solutions.

Funding and Growth Potential Having secured over 6 million dollars in funding and maintaining a lean revenue profile, HiberGene is indicative of a company poised for growth, offering potential partnership and investment opportunities in emerging diagnostic markets.

Technological Differentiation Using innovative LAMP technology, HiberGene provides cost-effective, simple-to-use testing solutions that can be integrated into near-patient settings, making it an attractive option for healthcare entities aiming to improve turnaround times and diagnostic accuracy.

Strategic Collaborations Partnerships with academic institutions and hospital networks suggest opportunities to collaborate on research, validation, and distribution channels, facilitating faster adoption of HiberGene’s diagnostic tests across healthcare systems globally.